Efficacy and safety of diphenylcyclopropenone among Chinese patients with steroid resistant and extensive alopecia areata
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
Topical immunotherapy has recently been found useful in the treatment of chronic and extensive Alopecia Areata (AA).

To evaluate the efficacy and safety of diphenylcyclopropenone (DPCP) use among Chinese patients with steroid resistant and extensive AA in our institute.

The medical records of 31 Chinese patients treated with DPCP were analysed retrospectively. The efficacy, adverse effects, and relapse rate of DPCP treatment were reviewed.

Thirty‐one (16 male, 15 female) Chinese patients with extensive, steroid resistant Alopecia Areata and a mean age of 28.9 years (SE 10.4) were treated. The mean age of onset was 17.8 years (SE 8.8) with an average disease duration of 11.2 years (SE 7.7). Ten patients had a history of atopy and 4 had a history of thyroid disease. Nail changes were found in 14 patients and a family history of AA was found in 2 patients. Thirteen patients (41.9%) had experienced total hair loss. Two patients abandoned the treatment due to severe side effects. Of the remaining 29 patients, 4 (13.8%), 7 (24.1%), 5 (17.2%), and 13 (44.8%) achieved >90% complete response, >50–90% partial response, >10–50% minimal response, and <10% no response hair regrowth, respectively. Adverse effects included pruritus, erythema, vesiculation, scaling, cervical lymphadenopathy, dyspigmentation and urticarial reactions. Relapse occurred (>25% hair loss) in 69.23% of patients after 18 months of follow up.

DPCP is an effective and tolerable treatment for Chinese patients with extensive, steroid resistant AA.
All Author(s) ListLuk NM, Chiu LS, Lee KC, Chau CTS, Lee VWY, Chang M, Lam YK, Lee HC
Journal nameJournal of the European Academy of Dermatology and Venereology
Volume Number27
Issue Number3
Pagese400 - e405
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesDermatology;Dermatology

Last updated on 2021-01-05 at 00:54